Mangoceuticals, Inc. Common Stock Cash Flow Conversion Efficiency
Mangoceuticals, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) has a cash flow conversion efficiency ratio of -0.021x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-260.51K) by net assets ($12.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mangoceuticals, Inc. Common Stock (MGRX) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Mangoceuticals, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of Mangoceuticals, Inc. Common Stock from 2021 to 2025. This chart illustrates how Mangoceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Mangoceuticals, Inc. Common Stock stock price today for real-time trading data and today's change.
Mangoceuticals, Inc. Common Stock Cash Flow Conversion Ratio Explained
Mangoceuticals, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mangoceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mangoceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Review financial agility of Mangoceuticals, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marvel Biosciences Corp
V:MRVL
|
0.049x |
|
Throgmorton Trust Plc
LSE:THRG
|
0.018x |
|
VITAL BATTERY METALS INC
F:C0O
|
N/A |
|
Gix Internet Ltd
TA:GIX
|
N/A |
|
Schroder Japan Growth Fund
LSE:SJG
|
0.001x |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
-0.002x |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
-0.522x |
|
Quantum Genomics SA
PA:ALQGC
|
3.110x |
Annual Cash Flow Conversion Efficiency for Mangoceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Mangoceuticals, Inc. Common Stock from 2021 to 2025. Also see how large is Mangoceuticals, Inc. Common Stock's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.20 Million | $-5.85 Million | -0.385x | -10.36% |
| 2024-12-31 | $13.95 Million | $-4.86 Million | -0.349x | +96.14% |
| 2023-12-31 | $774.75K | $-7.00 Million | -9.032x | -311.86% |
| 2022-12-31 | $614.03K | $-1.35 Million | -2.193x | -309.28% |
| 2021-12-31 | $-16.72K | $-17.52K | 1.048x | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more